|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 275.75 USD | -0.68% |
|
-0.92% | -4.26% |
| Capitalization | 148B 141B 131B 116B 210B 12,579B 233B 1,628B 601B 5,165B 556B 544B 22,540B | P/E ratio 2024 * |
29.3x | P/E ratio 2025 * | 23.4x |
|---|---|---|---|---|---|
| Enterprise value | 197B 187B 173B 154B 279B 16,688B 309B 2,160B 797B 6,852B 738B 722B 29,904B | EV / Sales 2024 * |
5.98x | EV / Sales 2025 * | 5.59x |
| Free-Float |
99.75% | Yield 2024 * |
3.28% | Yield 2025 * | 3.51% |
More valuation ratios
* Estimated data
More news
Last Transcript: Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -0.68% | ||
| 1 week | -0.92% | ||
| Current month | -2.52% | ||
| 1 month | -15.23% | ||
| 3 months | -16.17% | ||
| 6 months | -9.51% | ||
| Current year | -4.26% |
1 week
271.48
280.00
1 month
257.80321.22
Current year
257.80346.85
1 year
257.80346.85
3 years
209.00346.85
5 years
177.05346.85
10 years
130.09346.85
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 30/04/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 31/12/2019 |
David Reese
CTO | Chief Tech/Sci/R&D Officer | 61 | 25/07/2018 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 61 | 31/12/2012 |
Tyler Jacks
BRD | Director/Board Member | 63 | 31/12/2011 |
Robert Eckert
BRD | Director/Board Member | 69 | 31/12/2002 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.84% | 0 M€ | 0.00% | - | |
| 7.63% | 0 M€ | 0.00% | - | |
| 5.08% | 139 M€ | +25.85% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.68% | -0.92% | +2.46% | +30.76% | 148B | ||
| -0.50% | -1.69% | +33.70% | +227.51% | 720B | ||
| +0.15% | +1.05% | +17.78% | +106.85% | 488B | ||
| -0.25% | -2.05% | -3.36% | -9.83% | 359B | ||
| -0.51% | -3.21% | +17.68% | +40.01% | 310B | ||
| -2.69% | -0.83% | -2.65% | +39.08% | 255B | ||
| +0.49% | +0.59% | +0.35% | -32.00% | 231B | ||
| -0.29% | +0.02% | +3.82% | +27.09% | 208B | ||
| -0.58% | -2.20% | +2.97% | +18.22% | 201B | ||
| -2.03% | +0.04% | -11.15% | -51.55% | 145B | ||
| Average | -0.19% | -1.53% | +6.16% | +39.61% | 306.61B | |
| Weighted average by Cap. | -0.17% | -1.53% | +11.99% | +76.25% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 32.9B 31.31B 29.02B 25.81B 46.59B 2,792B 51.64B 361B 133B 1,146B 124B 121B 5,003B | 34.27B 32.62B 30.23B 26.89B 48.54B 2,909B 53.79B 376B 139B 1,194B 129B 126B 5,212B |
| Net income | 5.16B 4.91B 4.55B 4.04B 7.3B 437B 8.09B 56.62B 20.9B 180B 19.35B 18.94B 784B | 6.47B 6.16B 5.71B 5.08B 9.16B 549B 10.15B 71.06B 26.23B 225B 24.29B 23.77B 984B |
| Net Debt | 48.43B 46.09B 42.72B 37.99B 68.58B 4,110B 76.01B 532B 196B 1,687B 182B 178B 7,364B | 43.38B 41.28B 38.26B 34.03B 61.43B 3,681B 68.08B 476B 176B 1,511B 163B 159B 6,596B |
More financial data
* Estimated data
Employees
26,700
Sector
Pharmaceuticals
Calendar
03/02/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/24 | 275.75 $ | -0.68% | 2,791,398 |
| 09/12/24 | 277.63 $ | +1.85% | 3,222,458 |
| 06/12/24 | 272.58 $ | -0.64% | 3,970,337 |
| 05/12/24 | 274.33 $ | -1.41% | 3,186,985 |
| 04/12/24 | 278.26 $ | -0.02% | 4,174,137 |
Delayed Quote Nasdaq, December 10, 2024 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
275.75USD
Average target price
328.13USD
Spread / Average Target
+18.99%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition